Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
MINT Venture Partners is a global venture platform dedicated to building, accelerating, and investing in startups within the biotech and healthcare sectors. Founded by Dr. Jae-Hoon Song, MD, PhD, who serves as the CEO, MINT aims to create impactful businesses by collaborating with visionary founders and industry experts. The firm operates on a global scale, with a particular emphasis on the Asian market, especially South Korea. MINT's approach combines investment with structured support programs designed to foster innovation and growth in the healthcare landscape.
While specific metrics such as fund size or total assets under management (AUM) are not disclosed, MINT is recognized for its diverse portfolio that includes groundbreaking projects and technologies. The firm engages in various stages of company development, from pre-seed to growth equity, ensuring that they can support startups at different points in their journey. MINT's reputation is built on its commitment to advancing medicine through innovative solutions, making it a notable player in the venture capital ecosystem.
MINT Venture Partners focuses on the biotech and healthcare sectors, investing in innovative technologies and solutions that advance medical practices. The firm is particularly interested in startups that are developing cutting-edge solutions, including novel therapeutics, digital health applications, and diagnostic tools. MINT's investment strategy encompasses a range of stages, from pre-seed to growth equity, allowing them to engage with companies at various points in their development.
Key areas of interest for MINT include regenerative therapeutics, artificial intelligence applications in healthcare, and digital solutions aimed at improving patient outcomes. The firm actively supports startup creation through structured programs such as PRISM and CUBE, which are designed to nurture early-stage companies. Additionally, MINT accelerates growth through initiatives like Mint MD and Mint MedTech, which provide resources and mentorship to help companies scale effectively. By focusing on these sectors and stages, MINT aims to partner with founders who are committed to making a significant impact in the healthcare industry.
MINT Venture Partners boasts a diverse portfolio that highlights its commitment to innovation in the biotech and healthcare sectors. Notable projects include the development of novel antibody-drug conjugates (ADCs) for cancer treatment, regenerative therapeutics utilizing organoids, and the world's first mobile MRI technology. The firm also invests in digital health solutions aimed at preventing Alzheimer's disease and wearable devices designed for Parkinson's patients.
In addition to these projects, MINT is involved in the advancement of AI-powered 3D ultrasound technology and smart farming solutions that integrate healthcare with agricultural innovation. This diverse range of investments showcases MINT's strategic focus on transformative technologies that not only enhance medical practices but also improve patient care and outcomes. The firm's portfolio reflects its dedication to supporting visionary founders and groundbreaking ideas that have the potential to reshape the healthcare landscape.
Dr. Jae-Hoon Song - CEO: Dr. Song is the founder of MINT Venture Partners and brings extensive expertise in medicine and biotechnology to the firm. His leadership is pivotal in guiding the firm's investment strategy and fostering partnerships with visionary founders.
To pitch MINT Venture Partners, founders should visit their pitch URL at mintventures.bio. They welcome comprehensive pitches that detail the innovative aspects of the startup's technology and its potential impact on the healthcare sector. MINT is open to both warm introductions and cold applications, but a well-prepared pitch is essential for consideration.
MINT Venture Partners operates structured programs designed to support startup creation and growth. These include PRISM and CUBE, which focus on nurturing early-stage companies, and Mint MD and Mint MedTech, which provide resources and mentorship for growth acceleration. These programs are integral to MINT's strategy of fostering innovation in the biotech and healthcare sectors.
MINT Venture Partners invests across multiple stages, including pre-seed, seed, seed plus, Series A, and growth equity. This broad investment spectrum allows them to support startups at various points in their development journey.
Founders interested in pitching MINT Venture Partners can do so through their dedicated pitch URL at mintventures.bio. It is advisable to prepare a comprehensive pitch that outlines the innovative aspects of your technology and its potential impact on the healthcare sector.
MINT Venture Partners primarily focuses on the biotech and healthcare sectors. They are particularly interested in innovative technologies and solutions that advance medicine, including digital health applications and regenerative therapeutics.
While specific check sizes are not disclosed, MINT Venture Partners engages in investments across various stages, which typically range from early-stage funding to growth equity. This flexibility allows them to tailor their investments based on the needs of the startups they support.
MINT Venture Partners operates globally, with a strong focus on the Asian market, particularly South Korea. Their global presence enables them to identify and support innovative healthcare startups worldwide.
MINT Venture Partners offers structured support through programs like PRISM and CUBE for startup creation, as well as Mint MD and Mint MedTech for growth acceleration. These programs provide resources, mentorship, and strategic guidance to help startups succeed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.